4BaseCare

4BaseCare is an Illumina-backed precision oncology company headquartered in Singapore, developing cutting-edge genomic solutions to personalize cancer care for patients globally. Founded in 2018, the company combines advanced next-generation sequencing (NGS), AI-powered analytics, and real-world clinical data through its OncoTwin platform, which provides clinical decision support, AI-enhanced molecular tumor board intelligence, and clinical trial optimization. 4BaseCare has built the world's first Global Cancer Diversity Atlas—capturing genomic diversity from underrepresented populations across 15+ countries—and offers a comprehensive suite of genomic tests including tissue profiling, liquid biopsy, SoLiQ dual-source genomics, HRD testing, and germline cancer risk assessment. The company serves clinicians across 70+ cancer types and is committed to making precision oncology accessible and affordable across India, Southeast Asia, and the Middle East.